Clinical Trial Update: Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors [Phase 3]

View source ↗

Summary

Phase III study results for surufatinib in advanced pancreatic neuroendocrine tumors completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Surufatinib (Surufatinib)

Snippet

Sponsor: Hutchison Medipharma Limited | Conditions: Neuroendocrine Tumors | Phase 3 | Status: COMPLETED